Schott Pharma is to build a manufacturing facility in the USA.
The facility in Wilson, North Carolina, will primarily make prefillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications.
In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity.
The project will add 401 jobs to the region and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.
The new site will expand the US supply chain for in-demand syringes that deliver injectable medicines, vaccines, and other fields of applications.
It will allow Schott Pharma to triple its contribution of glass and polymer syringes to the US market by 2030.
Bringing production to the US will reduce lead times and slash transportation costs, as well as protect against future shortages of critical drugs and ensure pandemic preparedness.
“Wilson County stood out in a nationwide search for a number of reasons, particularly for its favourable pool of local talent and its proximity to the Research Triangle area, which hosts numerous universities, healthcare companies, and biopharma resources,” said Christopher Cassidy, President of Schott North America.
